Company Overview and News
OM Holdings Ltd (ASX:OMH) was one of the top performers on the ASX in 2017 and has continued this strong performance into 2018.
KUCHING: OM Materials (Sarawak) Sdn Bhd (OM Sarawak) is planning to invest in a sinter plant in Samalaju Industrial Park in Bintulu although no details have been provided on the investment costs and the timetable for the construction of the plant.
NEW capital market measures, a stronger ringgit, a stronger pipeline of initial public offerings (IPOs) and the upcoming general election are some of the key catalysts for Bursa Malaysia Bhd.
Executive chairman Hirotaka Suzuki(pic) said the US$400mil plant was currently producing 18,000 tonnes per month and operating below 80% of installed capacity. “We are now producing three standard grade products – manganese alloys, ferrosilicon and ferro manganese. Within two years of full operation, we plan to switch to production of value-added products for the steel industry,” he told StarBiz.
CMS group managing director Datuk Richard Curtis(filepic) said recently that the smelting plant would be able to achieve operational efficiency when all the 16 furnaces were in operations. He was optimistic that OM Sarawak would be able to return to the black.
Group managing director Datuk Richard Curtis(pic) told StarBiz the recovery in demand for the commodities has enabled the smelting plant in Samalaju Industrial Park, Bintulu to go on full-scale production.
KUCHING: OM Materials (Sarawak) Sdn Bhd (OM Sarawak) will produce a wide range of silicon and manganese alloys at its smelting plant in Samalaju Industrial Park, Bintulu by June 2017 to cater to steel producers making different types of products and applications, according to Australian company OM Holdings Ltd (OMH).
“OMH expects to continue to modify and increase production at its Sarawak plant by establishing another five furnaces for manganese alloys through first half of 2017, bringing potential total manganese alloy production to 200-250 kt (kiloton) per annum,” the company said in a filing with Australian Securities Exchange (ASX).
The recent rally mining commodities saw are more likely to have a negative impact in the long run, according to market analysts.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...